Journal of Molecular and Cellular Cardiology
Volume 48, Issue 3 , Pages 440-444 , March 2010

Role of matrix metalloproteinases in the inflammatory process of respiratory diseases

Received 23 April 2009 ,Revised 21 September 2009 ,Accepted 27 September 2009.

References 

  1. Vu T, Werb Z. Gelatinase B: structure, regulation, and function. In:  Parks WC,  Mecham RP editor. Matrix metalloproteinases. San Diego: Academic Press; 1998;p. 115–148
  2. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 2004;16:558–564
  3. Van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J. Leuk. Biol. 2007;82:1375–1381
  4. Manicorne AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Semin. Cell Dev. Biol. 2008;19:34–41
  5. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Stack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cell. Nature. 1997;385:729–733
  6. Ito A, Mukaiyama A, Itoh H, Nagase H, Thorgersen IB, Enghild JJ, et al. Degradation of interleukin 1 beta by matrix metalloproteinases. J. Biol. Chem. 1996;271:14657–14660
  7. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, et al. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 1999;68:729–777
  8. Li Q, Park PW, Wilson CL, Parks WC. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell. 2002;111:635–646
  9. Brew K. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta. 2000;1477:267–283
  10. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 2003;92:827–839
  11. Wong S, Belvisi MG, Birrell MA. Profiling of MMP/TIMP gene expression in human and rodent lung samples, and in models of airway inflammation. Proc. Am. Thor. Soc. 2005;2:A73
  12. Manoury B, Nenan S, Guénon I, Lagente V, Boichot E. Influence of early neutrophil depletion on MMPs/TIMP-1 balance in bleomycin-induced lung fibrosis. Int. Immunopharmacol. 2007;7:900–911
  13. Corbel M, Caulet-Maugendre S, Germain N, Lagente V, Boichot E. Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor, batimastat. J. Pathol. 2001;193:538–545
  14. Skiles JW, Gonnella NC, Jeng AY. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem. 2001;8:425–474
  15. Skotnicki JS, Levin JI, Killar LM. Matrix metalloproteinase inhibitors. In:  Bottomley KMK,  Bradshaw D,  Nixon JS editor. Metalloproteinases as Targets for Anti-Inflammatory Drugs. Progress in Inflammation Research; 1999;p. 17–57
  16. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994;54:4726–4728
  17. Watson SA, Morris TM, Collins HM, Bawden LJ, Hawkins K, Bone EA. Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Br. J. Cancer. 1999;81:19–23
  18. Delclaux C, Delacourt C, D'Ortho MP, Boyer V, Lafuma C, Harf A. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am. J. Respir. Cell Mol. Biol. 1997;14:288–295
  19. Corbel M, Lanchou J, Germain N, Boichot E, Lagente V. Modulation of airway remodeling-associated mediators by the antifibrotic compound pirfenidone and the matrix metalloproteinase inhibitor, batimastat during acute lung injury in mice. Eur. J. Pharmacol. 2001;426:113–121
  20. Birrell MA, Wong S, Dekkak A, De Alba J, Haj-Yahia S, Belvisi MG. Role of matrix metalloproteinases in the inflammatory response in human airway cell-based assays and in rodent models of airway disease. J. Pharmacol. Exp. Ther. 2006;318:741–750
  21. Birrell MA, Wong S, Hele DJ, McCluskie K, Hardaker E, Belvisi MG. Steroid-resistant inflammation in a rat model of chronic obstructive pulmonary disease is associated with a lack of nuclear factor-kappaB pathway activation. Am. J. Respir. Crit. Care Med. 2005;172:74–84
  22. Zhang Y, Xu J, Levin J, Hegen M, Li G, Robertshaw H, et al. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J. Pharmacol. Exp. Ther. 2004;309:348–355
  23. Mackarel AJ, Cottell DC, Russell KJ, FitzGerald MX, O'Connor CM. Migration of neutrophils across human pulmonary endothelial cells is not blocked by matrix metalloproteinase or serine protease inhibitors. Am. J. Respir. Cell Mol. Biol. 1999;20:1209–1219
  24. Betsuyaku T, Shipley JM, Liu Z, Senior RM. Gelatinase B deficiency does not protect against lipopolysaccharide-induced acute lung injury. Chest. 1999;116:17S–18S
  25. Betsuyaku T, Fukuda Y, Parks WC, Shipley JM, Senior RM. Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. Am. J. Pathol. 2000;157:525–535
  26. Solorzano CC, Ksontini R, Pruitt JH, Auffenberg T, Tannahill C, Galardy RE, et al. A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor alpha (TNF alpha) and abrogates endotoxin-induced lethality. Shock. 1997;7:427–431
  27. Nenan S, Lagente V, Planquois JM, Hitier S, Berna P, Bertrand CP, et al. Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur. J. Pharmacol. 2007;559:75–81
  28. Selman M, Cisneros-Lira J, Gaxiola M, ramirez R, Kudlacz EM, Mitchell PG, et al. Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in guinea-pigs. Chest. 2003;123:1633–1641
  29. Martin RL, Shapiro SD, Tong SE, Van Wart HE. Macrophage metalloelastase inhibitors. Prog. Respir. Res. 2001;31:177–180
  30. Trifilieff A, Walker C, Keller T, Kottirsch G, Neumann U. Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation. Br. J. Pharmacol. 2002;135:1655–1664
  31. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science. 1997;277:2002–2004
  32. Valença SS, Da Hora K, Castro P, Gonçalves de Moraes V, Carvalho L, Moraes Sobrino Porto LC. Emphysema and metalloelastase expression in mouse lung induced by cigarette smoke. Toxicol. Pathol. 2004;32:351–356
  33. Leclerc O, Lagente V, Planquois JM, Berthelier C, Artola M, Eichholtz T, et al. Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. Eur. Respir. J. 2006;27:1102–1109
  34. Nenan S, Planquois JM, Berna P, De Mendez I, Hitier S, Shapiro SD, et al. Analysis of the inflammatory response induced by rhMMP-12 catalytic domain instilled in mouse airways. Int. Immunopharmacol. 2005;5:511–524
  35. Churg A, Wang R, Wang X, Onnervik PO, Thim K, Wright JL. An MMP-9/-12 inhibitor prevents smoke-induced emphysema and small airway remodeling in guinea pigs. Thorax. 2007;62:706–713
  36. Le Quément C, Guénon I, Gillon JY, Valença S, Cayron-Elizondo V, Lagente V, et al. Involvement of MMP-12 in airway inflammation of mice exposed to cigarette smoke. Br. J. Pharmacol. 2008;154:1206–1215
  37. Le Quément C, Lagente V, Guenon I, Muzio V, Gillon JY, Boichot E. Anti-inflammatory properties of MMP inhibitors in experimental models of chronic obstructive pulmonary disease and lung inflammation. In: Matrix Metalloproteinases in Tissue Remodelling and Inflammation. Birkauser: Progress in Inflammation Research; 2008;p. 57–69
  38. Morris A, Kinnear G, Wan WY, Wyss D, Bahra P, Stevenson CS. Comparison of cigarette smoke-induced acute inflammation in multiple strains of mice and the effect of an MMP inhibitor on these responses. J. Pharmacol. Exp. Ther. 2008;327:851–862
  39. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev. 2003;22:177–203
  40. Van der Laan WH, Quax PH, Seemayer CA, Huisman LG, Pieterman EJ, Grimbergen JM, et al. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther. 2003;10:234–242
  41. Zacchigna S, Zentilin L, Morini M, Dell'Eva R, Noonan DM, Albini A, et al. AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther. 2004;11:73–80
  42. Johnson JL, Baker AH, Oka K, Chan L, Newby AC, Jackson CL, et al. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis. Circulation. 2006;113:2435–2444
  43. George SJ, Baker AH, Angelini GD, Newby AC. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther. 1998;5:1552–1560
  44. Vieillard-Baron A, Chergui K, Augarde R, Prin S, Page B, Beauchet A, et al. Cyclic changes in arterial pulse during respiratory support revisited by Doppler echocardiography. Hum. Gene Ther. 2003;14:861–869

PII: S0022-2828(09)00416-7

doi: 10.1016/j.yjmcc.2009.09.017

Journal of Molecular and Cellular Cardiology
Volume 48, Issue 3 , Pages 440-444 , March 2010

Article Tools

* Image Usage & Resolution